NICE Approves Lupus Nephritis Drug Restoring Kidney Function
Key Questions
What has NICE approved for lupus nephritis treatment?
NICE has greenlit a lupus nephritis (LN) treatment that restores kidney function in about 50% of patients. This approval bolsters organ protection options alongside EULAR recommendations.
How effective is the NICE-approved LN drug?
The treatment restores kidney function in approximately 50% of patients, setting a precedent for UK access with global implications for achieving remission. It complements calcineurin inhibitors like voclosporin.
What treatment approaches are emphasized for lupus nephritis?
Aggressive early combination therapies, such as glucocorticoids plus mycophenolate mofetil and belimumab, along with obinutuzumab for B-cell depletion, are recommended. These align with calls to treat LN aggressively from the outset to prevent complications.
NICE greenlights LN treatment restoring kidney function in ~50% patients, bolstering organ protection options alongside EULAR recs and CNIs like voclosporin; aggressive early combos (GC+MMF+belimumab), obinutuzumab B-cell depletion emphasized. Sets UK access precedent with global implications for remission.